Protagonist Therapeutics Secures $40,000,000 Series C Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f5c19a96-55ab-402d-90f3-43ff06e98cc3
Date 7/20/2015
Company Name Protagonist Therapeutics
Mailing Address 521 Cottonwood Drive Milpitas, CA 95035 USA
Company Description Protagonist Therapeutics is a U.S.-incorporated biotechnology company pursuing the discovery and development of disulfide-rich peptides (DRPs) as well differentiated alternatives to biologics, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which ideal small molecule and/or biologic options are unavailable.
Proceeds Purposes Proceeds from the financing will be used to advance Protagonist’s development candidate, PTG-100, into human clinical testing as a potential ‘oral targeted therapy’ for inflammatory bowel diseases (IBD), as well as to further the development of additional oral peptide drug candidates in the company’s product pipeline. PTG-100 is an orally stable peptide therapeutic that works by specifically blocking alpha-4-beta-7 integrin, a clinically validated target for IBD. Protagonist plans to initiate Phase 1 human clinical testing of PTG-100 by the end of 2015, and progress to Phase 1/2 clinical studies in IBD patients during 2016.
M&A Terms
Venture Investor Canaan Partners
Venture Investor Adage Capital Management
Venture Investor RA Capital
Venture Investor Foresite Capital
Venture Investor Johnson & Johnson Development Corporation